ATE284210T1 - Verfahren und zusammensetzung zur behandlung von krebs - Google Patents

Verfahren und zusammensetzung zur behandlung von krebs

Info

Publication number
ATE284210T1
ATE284210T1 AT98924758T AT98924758T ATE284210T1 AT E284210 T1 ATE284210 T1 AT E284210T1 AT 98924758 T AT98924758 T AT 98924758T AT 98924758 T AT98924758 T AT 98924758T AT E284210 T1 ATE284210 T1 AT E284210T1
Authority
AT
Austria
Prior art keywords
composition
treating cancer
preventing
disclosed
active compound
Prior art date
Application number
AT98924758T
Other languages
English (en)
Inventor
John M Pezzuto
Tapas K Dasgupta
Darrick S H L Kim
Mary Lou Schmidt
Konrad Marc Kuzmanoff
Lydia Ling-Indeck
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Application granted granted Critical
Publication of ATE284210T1 publication Critical patent/ATE284210T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT98924758T 1997-05-16 1998-05-14 Verfahren und zusammensetzung zur behandlung von krebs ATE284210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/857,413 US5962527A (en) 1995-03-21 1997-05-16 Method and composition for treating cancers
PCT/US1998/009703 WO1998051294A2 (en) 1997-05-16 1998-05-14 Method and composition for treating cancers

Publications (1)

Publication Number Publication Date
ATE284210T1 true ATE284210T1 (de) 2004-12-15

Family

ID=25325942

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924758T ATE284210T1 (de) 1997-05-16 1998-05-14 Verfahren und zusammensetzung zur behandlung von krebs

Country Status (6)

Country Link
US (1) US5962527A (de)
EP (2) EP1495754A3 (de)
AT (1) ATE284210T1 (de)
CA (1) CA2289684A1 (de)
DE (1) DE69828042T2 (de)
WO (1) WO1998051294A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869535A (en) * 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
EP1473301A3 (de) * 1997-06-04 2005-01-26 Cornell Research Foundation, Inc. Betulinol-Derivate
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
US6228850B1 (en) * 1997-09-30 2001-05-08 Dabur Research Foundation Antiangiogenic activity of betulinic acid and its derivatives
US6369109B1 (en) * 1998-10-28 2002-04-09 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor
WO2000046235A1 (en) * 1998-11-18 2000-08-10 Dabur Research Foundation Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors
ATE267837T1 (de) * 1999-09-09 2004-06-15 Dabur Res Foundation Betulinsäure-derivate mit antiangiogener wirkung, verfahren zur herstellung solcher derivate und deren verwendung für die behandlung tumorassoziierter angiogenese
EP1292562A1 (de) * 2000-05-23 2003-03-19 Univerzita palackeho V Olomouci Triterpenen derivaten
GB0012528D0 (en) 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
CA2418117A1 (en) * 2000-07-31 2003-01-30 The Nisshin Oillio, Ltd. Antitumor agent
AU8494601A (en) 2000-08-18 2002-03-04 Univ Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US20030003171A1 (en) 2001-03-28 2003-01-02 Usha Goswami Biologically active chloroform fraction of an extract obtained from a mangroone plant Salvadora persica L
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US6428823B1 (en) 2001-03-28 2002-08-06 Council Of Scientific & Industrial Research Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L
JPWO2003057224A1 (ja) * 2001-12-28 2005-08-25 日清オイリオグループ株式会社 アポトーシス誘導剤
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
CN100432094C (zh) * 2003-02-11 2008-11-12 诺瓦利克斯制药公司 抑制肿瘤生长的药物
KR100659771B1 (ko) 2003-04-04 2006-12-20 학교법인 현동학원 한국산 겨우살이 유기추출물로부터 항암 화합물 베루틴과베투린 산의 정제 및 이 추출물의 제조방법
US7026305B2 (en) * 2003-04-14 2006-04-11 Meharry Medical College Anti-HIV agents with dual sites of action
KR100559489B1 (ko) * 2003-08-05 2006-03-10 한국생명공학연구원 대추 추출물 및 그로부터 분리된 화합물을 유효성분으로함유하는 항암제 및 암전이 억제제
US8618082B2 (en) * 2004-03-02 2013-12-31 Wisconsin Alumni Research Foundation Lupeol anti-tumor agent and uses thereof
US20080227762A1 (en) * 2004-03-02 2008-09-18 Wisconsin Alumni Research Foundation Lupeol anti-tumor agent and uses thereof
US7282521B2 (en) * 2004-05-24 2007-10-16 University Of North Carolina At Chapel Hill Anti-retroviral moronic acid derivatives
US20060252733A1 (en) * 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
CA2641262A1 (en) * 2006-02-02 2007-08-16 University Of South Florida Withacnistin compounds for treatment of cancer
EP2371368A3 (de) * 2008-05-30 2012-08-22 Novelix Pharmaceuticals, Inc. Zusammensetzungen und Verfahren zur Behandlung von Entzündungen und hyperkeratotischen Läsionen
US20100104669A1 (en) * 2008-10-28 2010-04-29 Scheffler Armin Method for preparing an aqueous solution containing triterpenic acid, aqueous solution containing triterpenic acid, and use thereof
RS54239B1 (sr) 2010-06-04 2015-12-31 Bristol-Myers Squibb Company C-28 amidi modifikovanih derivata c-3 betulinske kiseline kao inhibitori sazrevanja hiv-a
US8754068B2 (en) 2010-06-04 2014-06-17 Bristol-Myers Squibb Company Modified C-3 betulinic acid derivatives as HIV maturation inhibitors
HUE026371T2 (en) 2011-01-31 2016-05-30 Bristol Myers Squibb Co C-28 amines from modified C-3 betulinic acid derivatives as anti-HIV matrices
US8846647B2 (en) 2011-01-31 2014-09-30 Bristol-Myers Squibb Company C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
CN104910239B (zh) * 2014-03-14 2018-12-07 中国科学院上海药物研究所 五环三萜类化合物及其制备方法、药物组合物和用途
CN104910238B (zh) * 2014-03-14 2017-08-11 中国科学院上海药物研究所 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途
US9808011B2 (en) 2014-12-15 2017-11-07 Biovectra Inc. Pentacyclic triterpene compounds and uses thereof
MA62195B1 (fr) * 2023-09-01 2025-07-31 École Supérieure Des Industries Du Textile Et De L'habillement (Esith) Composition ayant une activité antitumoral obtenues à partir de dérivés de molécules d’extrait de la plante d’alfa

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2683531B1 (fr) * 1991-11-13 1993-12-31 Rhone Poulenc Rorer Sa Nouveaux derives du lupane, leur preparation et les compositions pharmaceutiques qui les contiennent.
US5643884A (en) * 1993-08-09 1997-07-01 Glycomed Incorporated Lupane triterpenoid derivatives
US5869535A (en) * 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5658947A (en) * 1995-03-21 1997-08-19 Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma using betalinic acid
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
DE19532006A1 (de) * 1995-08-31 1997-03-06 Thomas Samland Medizinisches bzw. kosmetisches Präparat zur Vermeidung bzw. Abbau von Hautkrebs
JPH0987156A (ja) * 1995-09-19 1997-03-31 Pola Chem Ind Inc 光老化防止剤及び皮膚化粧料
US6670345B1 (en) * 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
EP0943620B1 (de) * 1998-03-18 2005-11-16 Dabur Pharma Ltd. Betulinsauer Derivate zur Hemmung von Krebswachstum

Also Published As

Publication number Publication date
CA2289684A1 (en) 1998-11-19
DE69828042D1 (de) 2005-01-13
DE69828042T2 (de) 2006-04-13
EP0981342A2 (de) 2000-03-01
EP0981342B1 (de) 2004-12-08
WO1998051294A3 (en) 1999-04-01
EP1495754A3 (de) 2009-07-29
WO1998051294A2 (en) 1998-11-19
EP1495754A2 (de) 2005-01-12
US5962527A (en) 1999-10-05

Similar Documents

Publication Publication Date Title
ATE284210T1 (de) Verfahren und zusammensetzung zur behandlung von krebs
ATE242632T1 (de) Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen
PT1076663E (pt) Derivados funcionalizados de alquilo e alcenilo de cadeia lateral de glicinamidas como inibidores de farnesil transferase
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
DE69533066D1 (de) Verbindungen und verfahren zur behandlung von krebs
ATE271385T1 (de) Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
ATE282591T1 (de) Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose
EP1037625A4 (de) Verfahren zur herstellung von arsentrioxyd-formulierungen und verfahren zur behandlung von krebs mit arsentrioxyd oder melarsoprol
MX9707192A (es) Compuestos triciclicos de carbamato, utiles para la inhibicion de la funcion de la proteina g y paratratamiento de enfermedades proliferativas.
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
EP1014995A4 (de) Zusammensetzungen und verfahren zur verhütung von restenosis nach wiedergefässbildung
DE60013266D1 (de) Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
EP0709090A3 (de) Zusammensetzungen zur Behandlung von resistenten Tumoren
DK0468012T3 (da) 17beta-substituerede 4-aza-5alfa-androstan-3-on-derivater og fremgangsmåde til fremstilling deraf
EP1085892A4 (de) Impfstrategie zur vorbeugung und behandlung von krebs
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
DE69721810D1 (de) Konjugate zur behandlung von prostatakrebs
DE69433793D1 (de) Phosphorderivate zur behandlung von aids
DE60008540D1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
EP0758894A4 (de) Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie
ATE394108T1 (de) Mittel und verfahren zum schutz, zur behandlung und zur reparatur von bindegewebe
DE69922364D1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE69911582D1 (de) Substituierte pyridino-arylpiperazine zur behandlung benigner prostatahyperplasie
EP1030681A4 (de) Verfahren und zusammensetzungen zur inhibierung von angiogenese sowie zur behandlung von krebs
NO990436D0 (no) FremgangsmÕte for behandling av bipolar forstyrrelse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties